CurveBeam AI (ASX:CVB) signed a commercial agreement with medical device manufacturer Stryker Australia for the Australia and New Zealand markets, according to a Tuesday filing with the Australian bourse.
Stryker will educate surgeons and promote the company's weight-bearing computed tomography imaging device HiRise for use in lower extremity orthopedic applications under the deal, the filing said.
The agreement, with an initial term of three years and a further term of two years, requires minimum referral volumes for sales and commissions to continue, per the filing.
CurveBeam AI shares were down 4% in afternoon trade Friday.
Price (AUD): $0.11, Change: $-0.0050, Percent Change: -4.35%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。